US2003167496A1PendingUtilityA1
Transgenic non-human mammals carrying human pituitary tumor transforming gene (PTTG) sequences
Priority: Nov 21, 1996Filed: Jun 21, 2002Published: Sep 4, 2003
Est. expiryNov 21, 2016(expired)· nominal 20-yr term from priority
A01K 2217/05Y10S435/81A61K 48/00A61K 38/00A61P 35/00C07K 14/47Y10S435/975
49
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed is a transgenic non-human mammal, which carries in its cells an exogenously supplied human pituitary tumor transforming gene (PTTG) polynucleotide sequence.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A transgenic non-human mammal, wherein the non-human mammal carries in its cells at least one exogenous nucleic acid comprising a polynucleotide having a nucleotide sequence consisting of:
(A) contiguous nucleotide positions 95-700 of SEQ ID NO:3; (B) a degenerate sequence of (A); or (C) a sequence complementary to (A) or (B).
2 . The transgenic non-human mammal of claim 1 , wherein the polynucleotide encodes a PTTG protein having an amino acid sequence of SEQ ID NO:4.
3 . The transgenic non-human mammal of claim 1 , wherein the non-human mammal is a mouse.
4 . The transgenic non-human mammal of claim 1 , wherein the polynucleotide is operatively linked to a promoter.
5 . The transgenic non-human mammal of claim 4 , wherein the promoter is an inducible promoter and/or a tissue specific promoter.
6 . The transgenic non-human mammal of claim 4 , wherein the polynucleotide is operatively linked to the promoter, such that transcription of the polynucleotide results in an antisense mRNA complementary to contiguous nucleotide positions 95-700 of SEQ ID NO:3.
7 . The transgenic non-human mammal of claim 4 , wherein the polynucleotide further comprises a mutation, such that transcription and translation result in inactive human PTTG protein being produced.Join the waitlist — get patent alerts
Track US2003167496A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.